Canadian Medical Center Co. announces the opening of the nomination period for the board of director’s membership
| Element List | Explanation |
|---|---|
| Introduction | Canadian Medical Center Co. announces the opening of the nomination period for membership of the Board of Directors for the upcoming term, which will commence on December 28, 2025 (08 Rajab 1447H) for a four-year term ending on December 27, 2029 (21 Sha’ban 1451H). Those who wish to nominate themselves and meet the conditions and criteria for membership of the Board of Directors must submit their nomination applications within the specified period and in accordance with the details stated in this announcement. |
| Type of Assembly | New Session |
| Term Start Date | 2025-12-28 |
| Term End Date | 2029-12-27 |
| Number of members | 5 |
| Nomination Start Date | 2025-09-03 Corresponding to 1447-03-11 |
| Nomination End Date | 2025-10-02 Corresponding to 1447-04-10 |
| Applications Submission Method | Nomination applications and required forms must be submitted before the end of the nomination period specified above, during the company’s official working hours (from 8:00 AM to 4:00 PM), through one of the following methods: |
- Email: Investor.relation@canadian-mc.com
- Hand delivery addressed to the Secretary of the Board of Directors at the company’s headquarters located in Dammam, Main Administration Building – Al-Bustan District – Al-Ammar Avenue Complex – Building No. (1) – 3rd Floor.
2. Applicants wishing to nominate themselves must disclose their desire by submitting a written notification to the company’s management within the specified period and dates in accordance with applicable policies, regulations, and instructions (attached), along with providing all required identification documents such as (National ID, family card – if applicable – passport for non-Saudi nominees, and any other documents required by the company to meet regulatory requirements).
3. Provide a signed copy of the CV Form No. (3) issued by the Capital Market Authority for nomination to the Board of Directors, in both Arabic and English. (attached)
4. Provide CV Form No. (1) issued by the Capital Market Authority in both Arabic and English. (attached)
5. The nominee must not be a member of the boards of more than five joint-stock companies listed on the stock exchange at the same time.
6. The nominee must not be prohibited by regulatory authorities from working in joint-stock companies.
7. A statement of the listed joint-stock companies in which the nominee still serves as a member.
8. A statement of companies, institutions, or entities managed or owned by the nominee that carry out activities similar to the company’s business.
9. A nominee who has previously served as a member of the board of a joint-stock company must provide a statement from that company regarding the last board term, including the following information:
A- Number of board meetings held each year of the term.
B- Number of meetings attended in person and the attendance percentage.
C- The permanent committees in which the member participated, the number of meetings held by each committee during every year of the term, the number of meetings the member attended, and the percentage of attendance relative to the total meetings.
10. The nominee must also disclose any case of conflict of interest, including having a direct or indirect interest in the company’s contracts or business, or engaging in any activity that competes with the company or its subsidiaries.
The Nomination and Remuneration Committee will take into account the diversity of the nominee’s academic qualifications and professional experience when evaluating candidates, giving priority to individuals with appropriate skills required for board membership. Voting at the General Assembly will be limited to those who have nominated themselves in accordance with the above-mentioned regulations and requirements.
The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate.